New drug aims to slow kidney damage in IgA nephropathy
NCT ID NCT07354932
First seen Jan 28, 2026 · Last updated Jun 17, 2026 · Updated 17 times
Summary
This study tests an experimental drug called SHR-2173 in people with IgA nephropathy, a kidney disease. The goal is to see if the drug can reduce protein in the urine, a sign of kidney damage. About 84 adults will receive either the drug or a placebo for 48 weeks, and their kidney function will be monitored.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY IGA NEPHROPATHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, 200025, China
Contact
-
The First Affiliated Hospital of Sun Yat-sen University
RECRUITINGGuangzhou, Guangdong, 510080, China
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.